Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)

The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-modifying options are in the late-phase pipeline (e.g., Eli Lilly’s remternetug, Roche’s trontinemab). Lundbeck / Otsuka’s Rexulti, the first drug approved by the FDA for the treatment of agitation in AD, will likely face competition from numerous additional emerging options (e.g., Axsome’s AXS-05 [Auvelity], BMS’s KarXT [Cobenfy]). Established and emerging players must understand today’s treatment landscape and patient journey to optimize future uptake and competitive positioning) are in the pipeline. Established and emerging players must understand today’s treatment landscape and patient journey to optimize future uptake and competitive positioning.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AD patients?
• How have Leqembi and Kisunla been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of AD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of AD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Markets covered: United States

Key drugs: Leqembi, Leqembi Iqlik, Kisunla, donepezil, galantamine, memantine IR, Namenda XR, Namzaric, rivastigmine, rivastigmine patch, atypical antipsychotics, Rexulti, Nuplazid, antidepressants